Sensorion SAS: Strong Financial Position and Promising Clinical Progress Justify Buy Rating

In a report released today, Clémence Thiers from Stifel Nicolaus maintained a Buy rating on Sensorion SAS (RFM – Research Report), with a price target of €1.50.

Clémence Thiers has given his Buy rating due to a combination of factors that highlight Sensorion SAS’s promising future prospects. The company has strengthened its financial position significantly through two major funding rounds in 2024, raising a total of approximately EUR65.5 million. This financial boost has left Sensorion with a robust cash position of EUR77 million by the end of the year, providing financial visibility until the first quarter of 2026.
Furthermore, Sensorion has made noteworthy progress in its clinical programs, particularly with its GTx program. The Audiogene P1/2 study has advanced rapidly, with the first patient cohort enrolled within months, and preliminary results showing no safety concerns and signs of behavioral improvement. The upcoming year is expected to bring further catalysts, including the completion of the second cohort enrollment and anticipated FDA feedback, which could define the clinical path forward. Despite some uncertainties around SENS-401, the company’s strong execution and strategic positioning in the market support the Buy rating with a price target of EUR1.5.

According to TipRanks, Thiers is ranked #9056 out of 9339 analysts.

In another report released on March 7, H.C. Wainwright also reiterated a Buy rating on the stock with a €3.00 price target.